Roche has agreed to acquire GenMark, a multiplex molecular diagnostic (MD) solutions provider for infectious diseases, including bloodstream, respiratory and gastrointestinal infections. The deal, which is worth approximately US$1.8 B, gives Roche access to GenMark’s eSensor® detection technology which facilitates sample-to-answer syndromic MD tests. Through GenMark, Roche will be able to expand its offerings to include molecular multiplexing and build further on its COVID-19 testing capabilities.